Phase I clinical studies have shown that 99mTc-labeled ADAPT6 [21] and DARPin G3 [22] provide discrimination between HER2-positive and HER2-negative breast cancer tumors and are potential candidates for further clinical development. Here, ERBB2 is linked to breast carcinoma.